• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Rest Easy: Benzos, Z-Drugs, and Dementia

Rest Easy: Benzos, Z-Drugs, and Dementia

December 31, 2020
James Jenkins, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
James Jenkins, MD. Dr. Jenkins has disclosed that he has stock in Alkermes, Sage Therapeutics, Teva Pharmaceutical Industries, Trevena, and Viatris. Dr. Aiken has reviewed this article and has found no evidence of bias pertaining to this educational activity.

Review of: Osler M and Jorgensen MB, Am J Psych 2020;177(6):497–505

Study TYPE: Epidemiologic case-control

Few psychotropics stir controversy like the benzodiazepines. While they work well for anxiety and insomnia, their risks of abuse and dependence have always nagged at us. More recently, some research has suggested that long-term use increases the risk of dementia. Those studies did not control for subjects’ underlying diagnoses, and this new study partially overcomes that problem by focusing on a homogenous diagnostic group.

This cohort and nested case-control study drew its data from Danish hospital and pharmacy registries. The cohort of roughly 235,000 subjects was comprised of patients who presented for their first hospitalization for a mood disorder. These patients were assessed for dementia at that first visit and followed for 3–11 years. The primary outcome was the difference in the rate of dementia between those who were started on a benzodiazepine or z-hypnotic and those who were not.

Dementia can present with symptoms of depression, so it’s possible that some of the patients who converted to dementia were in the early phase of cognitive decline at the start of the study. To control for that, patients who converted to dementia in the first two years were analyzed separately.

The researchers adjusted for a number of variables including gender, age, marital status, education, depression subtype, year of diagnosis, psychotropic medication use, and comorbidity. The thoroughness of their adjustments and generalizability are what make this study stand apart from prior, similar case-control and prospective studies. The data collected from the registries allowed the researchers to see all diagnoses, prescribed medications, amounts of medications filled, hospitalizations, timing of diagnoses, and even data prior to study entry.

In their analysis, the authors found that out of the study cohort, 4% were diagnosed with dementia. Unexpectedly, there was a decreased risk of dementia in the first 2 years after study entry if a benzodiazepine or z-drug was prescribed (hazard ratio 0.70; range 0.66–0.74). For years 2 through 20 after study entry, there was no association between dementia and use of benzodiazepines or z-drugs, even when stratifying based on number of prescriptions, duration of use, combined use, and half-life.

TCPR’s Take
While it does not completely close the door on the controversy, this study significantly weakens the links between benzos, z-hypnotics, and dementia. However, these medications do have other cognitive side effects separate from any dementia risk, and their use still warrants caution in the elderly due to their risks of falls, traffic accidents, and respiratory suppression. Low doses of short-acting benzodiazepines like lorazepam and oxazepam minimize those risks.
General Psychiatry
KEYWORDS anxiety benzodiazepines dementia deprescribing generalized-anxiety-disorder geriatric-psychiatry hypnotics
    James Jenkins, MD.

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2021
    SUBSCRIBE NOW
    Table Of Contents
    Beta Blockers and Depression: The Controversy Revisited
    The Queen’s Gambit
    How to Use Lamotrigine
    Probiotics in Psychiatry
    Rest Easy: Benzos, Z-Drugs, and Dementia
    CME Post-Test - Mind-Gut Connection, TCPR, January 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.